{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:10:24Z","timestamp":1760235024679,"version":"build-2065373602"},"reference-count":5,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T00:00:00Z","timestamp":1625788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Over the last decades, cancer has become one of the most relevant health issues at a worldwide level [...]<\/jats:p>","DOI":"10.3390\/pharmaceutics13071045","type":"journal-article","created":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T04:14:57Z","timestamp":1625804097000},"page":"1045","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cancer Mechanisms and Emerging Therapies"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3030-8626","authenticated-orcid":false,"given":"Diana","family":"Gulei","sequence":"first","affiliation":[{"name":"MEDFUTURE\u2014Research Center for Advanced Medicine, \u201cIuliu-Hatieganu\u201d University of Medicine and Pharmacy, Marinescu 23 Street\/Louis Pasteur 4\u20136 Street, 400337 Cluj-Napoca, Romania"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8686-4106","authenticated-orcid":false,"given":"Alice","family":"Indini","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4186-5345","authenticated-orcid":false,"given":"Carmen","family":"Jer\u00f3nimo","sequence":"additional","affiliation":[{"name":"Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)\/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)\/Porto Comprehensive Cancer Center (Porto.CCC), R. Dr. Ant\u00f3nio Bernardino de Almeida, 4200-072 Porto, Portugal"},{"name":"Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar, University of Porto (ICBAS-UP), Rua Jorge Viterbo Ferreira 228, 4050-513 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0345-0993","authenticated-orcid":false,"given":"Cristina-Adela","family":"Iuga","sequence":"additional","affiliation":[{"name":"MEDFUTURE\u2014Research Center for Advanced Medicine, \u201cIuliu-Hatieganu\u201d University of Medicine and Pharmacy, Marinescu 23 Street\/Louis Pasteur 4\u20136 Street, 400337 Cluj-Napoca, Romania"},{"name":"Department of Pharmaceutical Analysis, Faculty of Pharmacy, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, Louis Pasteur Street 6, 400349 Cluj-Napoca, Romania"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8412-3136","authenticated-orcid":false,"given":"Francesco","family":"Grossi","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Department of Medicine and Surgery, University of Insubria, ASST dei Sette Laghi, 21100 Varese, Italy"}]}],"member":"1968","published-online":{"date-parts":[[2021,7,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Lobo, J., Cardoso, A.R., Miranda-Gon\u00e7alves, V., Looijenga, L.H.J., Lopez, M., Arimondo, P.B., Henrique, R., and Jer\u00f3nimo, C. (2021). Targeting Germ Cell Tumors with the Newly Synthesized Flavanone-Derived Compound MLo1302 Efficiently Reduces Tumor Cell Viability and Induces Apoptosis and Cell Cycle Arrest. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13010073"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Ding, H., Xu, T., Zhang, J., Tolmachev, V., Oroujeni, M., Orlova, A., Gr\u00e4slund, T., and Vorobyeva, A. (2021). Affibody-Derived Drug Conjugates Targeting HER2: Effect of Drug Load on Cytotoxicity and Biodistribution. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13030430"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Chizenga, E.P., and Abrahamse, H. (2021). Biological Therapy with Complementary and Alternative Medicine in Innocuous Integrative Oncology: A Case of Cervical Cancer. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13050626"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Indini, A., Rijavec, E., Ghidini, M., Cortellini, A., and Grossi, F. (2021). Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13050653"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Cenariu, D., Zimta, A.A., Munteanu, R., Onaciu, A., Moldovan, C.S., Jurj, A., Raduly, L., Moldovan, A., Florea, A., and Budisan, L. (2021). Hsa-miR-125b Therapeutic Role in Colon Cancer Is Dependent on the Mutation Status of the TP53 Gene. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13050664"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/13\/7\/1045\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:28:07Z","timestamp":1760164087000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/13\/7\/1045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,9]]},"references-count":5,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["pharmaceutics13071045"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics13071045","relation":{},"ISSN":["1999-4923"],"issn-type":[{"type":"electronic","value":"1999-4923"}],"subject":[],"published":{"date-parts":[[2021,7,9]]}}}